Back

Superior cardiorenal protection with tirzepatide over dulaglutide in heart failure with preserved ejection fraction: a large-scale propensity score–matched real-world analysis

29 August 2026 (08:35 - 08:45)
Organised by: Logo
Congress Presentation Part of: Moving the needle further in HFrEF therapy Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Iffat Zahan

Harefield Hospital, Harefield (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: a large southeast asian propensity-weighted cohort study
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides
Presentation thumbnail
Efficacy of sacubitril/valsartan on mortality in asymptomatic hypotensive HFrEF: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides
Presentation thumbnail
The FINO-HF trial: a randomised comparison of finerenone versus spironolactone in patients with heart failure with reduced ejection fraction - biomarker and clinical outcomes
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides
Presentation thumbnail
The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract Slides
Presentation thumbnail
Glucagon-like peptide-1 receptor agonism in heart failure with improved ejection fraction; PRAISE-HFiEF
Assistant Professor I. Helmy (Cleveland, US)
Abstract Slides

Access the full session

Session thumbnail
Moving the needle further in HFrEF therapy
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:35 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of GLP-1 agonists in obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized placebo-controlled trials.
1 September 2025
thumbnail
Congress Presentation
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
31 August 2019
thumbnail
Congress Presentation
Comparative outcomes between empagliflozin and dapagliflozin in heart failure: real world multi-center cohort study
31 August 2024
thumbnail
Congress Presentation
Cardiorenal syndrome and death risk in patients with heart failure or chronic kidney disease: an unmet cardiorenal need?
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources